paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism
Conditions
Secondary Hyperparathyroidism, Hemodialysis
Trial Timeline
May 1, 2011 → Apr 1, 2012
NCT ID
NCT01341782About paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo is a phase 3 stage product being developed by AbbVie for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT01341782. Target conditions include Secondary Hyperparathyroidism, Hemodialysis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01341782 | Phase 3 | Completed |
Competing Products
20 competing products in Secondary Hyperparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| KHK7580 + KRN1493 | Kyowa Kirin | Phase 2/3 | 65 |
| KHK7580 | Kyowa Kirin | Phase 1 | 33 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| Cinacalcet HCl | Kyowa Kirin | Approved | 85 |
| KHK7580 + Cinacalcet Hydrochloride | Kyowa Kirin | Phase 3 | 77 |
| Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493 | Kyowa Kirin | Phase 2 | 52 |
| dirucotide + Placebo | Eli Lilly | Phase 2/3 | 65 |
| dirucotide | Eli Lilly | Phase 2/3 | 65 |
| Paricalcitol + Calcitriol | AbbVie | Pre-clinical | 23 |
| Paricalcitol + Calcifediol | AbbVie | Approved | 85 |
| Paricalcitol + Darbepoetin alfa | AbbVie | Approved | 85 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |